Retatrutide vs Zepbound: The Triple-Agonist Question for Obesity

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited

Investigational drug notice

Retatrutide is an investigational drug. It has not received FDA approval and is not available outside clinical trials. FormBlends does not sell, supply, prescribe, or facilitate access to retatrutide. This page discusses published clinical trial data for educational purposes. Anyone seeking pharmacotherapy for weight management should work with a licensed clinician using FDA-approved medications.

Key Takeaways

• Zepbound is tirzepatide, FDA-approved for chronic weight management in November 2023
• SURMOUNT-1 (Jastreboff et al., NEJM 2022): 22.5% mean weight loss at 15 mg tirzepatide over 72 weeks
• Retatrutide phase 2 (Jastreboff et al., NEJM 2023): 24.2% at 12 mg over 48 weeks
• Cross-trial gap is small (~1.7 percentage points at endpoint) and the comparison has well-known limits
• Retatrutide adds glucagon receptor agonism to the GLP-1/GIP dual mechanism of tirzepatide; the liver-fat and energy-expenditure benefits look distinctive in phase 2

Direct answer

Cross-trial, retatrutide phase 2 produced slightly more weight loss than the SURMOUNT-1 trial of tirzepatide. The numbers (24.2% versus 22.5% at top doses) come from trials of different durations, sample sizes, and phases, so they should not be read as a precise efficacy gap. Zepbound is approved and available. Retatrutide is investigational and not legally accessible outside trials. For most patients in 2026, the practical comparison is moot because only one of the two drugs is prescribable.

Table of contents

1. Naming and brand context
2. The SURMOUNT-1 trial in detail
3. The retatrutide phase 2 trial in detail
4. Side-by-side: what changes at the molecular level
5. Liver fat and metabolic effects beyond weight
6. The 48 vs 72 week duration question
7. Cost, access, and insurance coverage
8. Cardiovascular and long-term outcome evidence
9. Side effects, dose by dose
10. The contrary view: Zepbound is probably enough
11. FAQ
12. Sources

Naming and brand context

Tirzepatide is the generic drug name. Eli Lilly markets it under two brands: Mounjaro for type 2 diabetes (approved May 2022) and Zepbound for chronic weight management in adults with obesity or overweight plus at least one comorbidity (approved November 2023). The molecule is the same in both brands; the indications and supporting trial programs differ.

Retatrutide is a development-stage molecule from the same manufacturer. Lilly has positioned it through investor materials as a next-generation weight-loss therapy aimed at the higher-efficacy end of the market. Brand naming has not been announced. The active trial program is called TRIUMPH.

The strategic context matters because Lilly is essentially developing a successor to Zepbound. If retatrutide approves, Lilly will run both drugs in parallel rather than pulling Zepbound from the market. Patients who respond well to Zepbound will likely stay on Zepbound.

The SURMOUNT-1 trial in detail

SURMOUNT-1 was the pivotal phase 3 trial supporting Zepbound's obesity approval.

• Citation: Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
• Design: Randomized, double-blind, placebo-controlled, 72-week duration. Participants received tirzepatide 5 mg, 10 mg, 15 mg, or placebo once weekly, all alongside lifestyle intervention.
• Population: 2,539 adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity. Excluded type 2 diabetes.
• Mean baseline: Weight 105 kg, BMI 38.0, age 44.9.
• Primary outcome (mean percent weight change at 72 weeks, treatment regimen estimand):
  • 5 mg: -15.0%
  • 10 mg: -19.5%
  • 15 mg: -20.9%
  • Placebo: -3.1%
• Efficacy estimand (treatment policy): 22.5% at 15 mg. This is the figure most commonly cited.
• Categorical response: 91% of 15 mg patients lost ≥5% of body weight; 57% lost ≥20%; 36% lost ≥25%.

The retatrutide phase 2 trial in detail

The retatrutide phase 2 trial is the primary data source for any comparison to Zepbound.

• Citation: Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. NEJM 2023;389:514-526.
• Design: Randomized, double-blind, placebo-controlled, 48-week duration. Dose-finding phase 2.
• Population: 338 adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity, without diabetes.
• Mean baseline: Weight 107.7 kg, BMI 37.3, age 48.
• Primary outcome (mean percent weight change at 48 weeks):
  • 1 mg: -8.7%
  • 4 mg: -17.1%
  • 8 mg: -22.8%
  • 12 mg: -24.2%
  • Placebo: -2.1%
• Categorical response at 12 mg: 100% achieved ≥5% weight loss; 83% achieved ≥15%; 48% achieved ≥25%.
• Curve characteristics: Weight loss had not plateaued at week 48 in any active arm.

Side-by-side: what changes at the molecular level

Tirzepatide is a synthetic peptide that activates two receptors: GLP-1 and GIP. It is biased toward GIP affinity, meaning it has stronger GIP receptor activity than native GIP at therapeutic doses. The dual-receptor mechanism appears to produce more weight loss than single GLP-1 agonists like semaglutide.

Retatrutide adds a third receptor: glucagon. The molecule retains GLP-1 and GIP agonism while adding balanced glucagon activity. The pharmacology challenge in designing a triple agonist is keeping all three activities at proportions that produce the desired metabolic profile without runaway glucose elevation from glucagon. Retatrutide's design appears to thread that needle: glycemic control is preserved (and improved in diabetic patients per Rosenstock et al., Lancet 2023), while the glucagon-mediated effects on energy expenditure and liver fat are accessible.

Two phase 2 observations support the mechanistic story:

• The dose-response for retatrutide weight loss is steeper at low doses than for tirzepatide. The 4 mg retatrutide arm produced 17.1% weight loss, comparable to mid-dose tirzepatide
• Liver fat reductions in patients with elevated baseline hepatic steatosis appeared more pronounced than what tirzepatide trials have shown

Liver fat and metabolic effects beyond weight

Both drugs reduce liver fat, but the magnitude appears to differ in cross-trial comparison. In a subset analysis from retatrutide phase 2, patients with baseline hepatic fat fraction ≥10% had reductions averaging over 80% at high retatrutide doses by 48 weeks. Tirzepatide trials (SYNERGY-NASH) showed roughly 50-60% reductions over similar durations at top doses.

The likely mechanism: glucagon receptor activation in hepatocytes directly promotes fatty acid oxidation. The dual-agonist tirzepatide reduces liver fat primarily through systemic weight loss and insulin resistance improvements; the triple agonist may add a more direct hepatic effect.

The clinical relevance: patients with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) or MASH (formerly NASH) may eventually find retatrutide a useful targeted therapy. The MASH-specific trial for retatrutide is part of the broader phase 3 program. Tirzepatide has the SYNERGY-NASH trial that has reported positive results.

The 48 vs 72 week duration question

Comparing 48-week retatrutide data to 72-week Zepbound data is not apples-to-apples. The fair comparison can be approached two ways:

Matched timepoint (48 weeks): Tirzepatide in SURMOUNT-1 reached roughly 19% mean weight loss at week 48 (estimated from the published curve, not a formal endpoint). Retatrutide at 48 weeks was 24.2%. The gap at matched timepoint is wider than the gap at trial endpoint, around 5 percentage points.

Endpoint comparison: Retatrutide 24.2% at 48 weeks vs Zepbound 22.5% at 72 weeks. The gap is about 1.7 percentage points.

Projected: The retatrutide curve at 48 weeks was still descending. Projected to 72 weeks, mean weight loss might reach 28-31%. That projection is speculative and would need to be confirmed by phase 3 data running at longer durations.

None of these readings produces a definitive answer. The directional signal across multiple approaches is the same: retatrutide phase 2 looks more potent than SURMOUNT-1 tirzepatide. The magnitude is uncertain.

Cost, access, and insurance coverage

Zepbound list price as of May 2026 is approximately $1,060 per month. Through Lilly's self-pay program (introduced August 2024 for 2.5 mg and 5 mg vials, expanded through 2025-2026), cash-pay pricing is closer to $349-$549 per month depending on dose. Insurance coverage for Zepbound has improved year-over-year but remains inconsistent: most commercial plans cover it with prior authorization and BMI requirements; Medicare and most Medicaid plans do not cover it for obesity (separate from diabetes coverage of Mounjaro).

Retatrutide has no commercial price because it is not approved. Industry expectation is that launch pricing would match other branded incretin drugs in the $1,000-1,300 per month list range. Self-pay programs would likely follow within 12-18 months of launch. Initial insurance coverage would face the same approval and BMI hurdles that Zepbound has navigated.

For patients comparing options today, the cost question is essentially zero-vs-Zepbound, because retatrutide is not an option. The relevant cost comparison is Zepbound vs Wegovy vs compounded alternatives.

Cardiovascular and long-term outcome evidence

The SELECT trial of semaglutide (Lincoff et al., NEJM 2023) established that GLP-1 receptor agonism reduces major adverse cardiovascular events in patients with obesity and established cardiovascular disease (20% relative risk reduction over a mean 39.8 months follow-up).

Tirzepatide has the SURPASS-CVOT trial (cardiovascular outcomes in T2D, anticipated readout late 2025-2026) and SURMOUNT-MMO (morbidity and mortality in obesity, later readout). Phase 2 and 3 trials so far show favorable changes in cardiovascular risk factors (blood pressure, lipids, glycemia) but the hard outcome data is pending.

Retatrutide has no cardiovascular outcome trial published. Surrogate markers in phase 2 (BP, lipids, glycemia, liver fat) all moved in favorable directions. The hard outcome story is years away.

For patients with established cardiovascular disease, the available evidence favors semaglutide today and tirzepatide pending readouts. Retatrutide will need to build its CV evidence base before it competes on outcomes.

Side effects, dose by dose

Adverse event	Tirzepatide 15 mg (SURMOUNT-1)	Retatrutide 12 mg (phase 2)
Nausea	~33%	~36%
Diarrhea	~21%	~27%
Vomiting	~15%	~16%
Constipation	~17%	~14%
Decreased appetite	~10%	~13%
Hair loss/thinning	~5%	~6%
Discontinuation for AE	~7%	~6-12% varied by dose
Pancreatitis (cases)	Rare	Rare, none confirmed in phase 2

The differences are within the noise of cross-trial comparison. Phase 3 retatrutide data will be the authoritative source on side-effect rates.

The contrary view: Zepbound is probably enough

The "newer must be better" framing is rarely accurate in obesity pharmacotherapy. A few reasons Zepbound may remain the right choice for many patients even after retatrutide approves:

Evidence depth. Zepbound has phase 3 data from SURMOUNT-1, SURMOUNT-2 (in type 2 diabetes), SURMOUNT-3 (after lifestyle lead-in), and SURMOUNT-4 (maintenance). The evidence base spans roughly 5,000 patients in obesity-specific studies plus the broader tirzepatide diabetes program. Retatrutide has 338 phase 2 patients and several thousand more in active phase 3. The certainty gap will narrow but not close.

Insurance and access infrastructure. Patients on Zepbound today have already navigated prior authorization, pharmacy supply, and dose titration. Switching introduces friction at every step.

Diminishing returns at the top of the curve. Going from 20% to 25% mean weight loss is harder to justify than going from 5% to 20%. The latter changes cardiovascular and metabolic risk profiles substantially. The former adds marginal benefit with proportionally higher risks of muscle loss, micronutrient gaps, and gallstones.

The "good enough" patient. Many patients reach a maintenance weight on Zepbound that produces the clinical outcomes they need (diabetes remission, sleep apnea improvement, joint pain reduction, fertility restoration). Pushing for more weight loss because a newer drug exists is rarely good medicine when the existing therapy is meeting clinical goals.

The honest take: retatrutide will probably matter most for the subset of patients where Zepbound is insufficient. For everyone else, the existing approved option will remain appropriate.

FAQ

Is Zepbound the same as Mounjaro? Same molecule (tirzepatide), different brand names. Zepbound is the obesity indication. Mounjaro is the type 2 diabetes indication.

Is retatrutide compounded available now? No. No legitimate compounding pathway exists for retatrutide.

When will retatrutide be FDA-approved? Projected 2027 or later, pending phase 3 readouts and FDA review.

If I take Zepbound, should I plan to switch to retatrutide? Not in advance. The vast majority of Zepbound responders will not have clinical reason to switch.

What is the maximum dose of Zepbound? 15 mg weekly is the maximum approved dose. Patients reach 15 mg through a standard titration schedule (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg over months).

Can I take retatrutide while on Zepbound? No. Combining incretin medications is not studied and is not clinically appropriate.

Does insurance cover Zepbound? Coverage varies widely. Most commercial plans cover with prior authorization. Medicare and most Medicaid plans do not cover Zepbound for obesity. Coverage policies change annually.

What is the difference between Zepbound and Wegovy? Wegovy is semaglutide (single GLP-1 agonist). Zepbound is tirzepatide (dual GLP-1/GIP agonist). Both are approved for chronic weight management. Tirzepatide produces more weight loss in cross-trial comparison.

Related guides

• What Is Retatrutide? The Triple-Agonist Obesity Drug Explained
• Retatrutide vs Mazdutide: Triple Agonist vs Dual Agonist, Lilly vs Innovent
• Retatrutide: Complete Guide to Eli Lilly's Triple Agonist
• Retatrutide for Weight Loss: How the Triple Agonist Works
• How Does Retatrutide Work? Triple Receptor Agonist Explained
• Retatrutide vs CagriSema: Triple Agonist vs GLP-1/Amylin Combination

Sources

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:205-216.
2. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. New England Journal of Medicine. 2023;389:514-526.
3. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide in Type 2 Diabetes: A Phase 2 Trial. The Lancet. 2023;402:529-540.
4. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024.
5. Garvey WT et al. Tirzepatide for Obesity Treatment in Adults With Type 2 Diabetes (SURMOUNT-2). The Lancet. 2023;402:613-626.
6. Wadden TA et al. Tirzepatide After Intensive Lifestyle Intervention in Adults with Overweight or Obesity (SURMOUNT-3). Nature Medicine. 2023.
7. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM. 2023.
8. FDA. Zepbound (tirzepatide) Prescribing Information. Approved November 2023.
9. FDA. Mounjaro (tirzepatide) Prescribing Information. Approved May 2022.
10. ClinicalTrials.gov. TRIUMPH phase 3 retatrutide program identifiers.
11. Eli Lilly Q1 2026 earnings call transcript and investor presentation.
12. Endocrine Society Clinical Practice Guideline on Pharmacological Management of Obesity, 2024 Update.

Footer disclaimers

Platform Disclaimer. FormBlends is a telehealth platform connecting patients with independent licensed providers and U.S.-based pharmacies. Prescribing and dispensing decisions are made by licensed clinicians and pharmacies, not by FormBlends.

Compounded Medication Notice. Compounded semaglutide and compounded tirzepatide are prepared by state-licensed 503A compounding pharmacies in response to individual prescriptions. They are not FDA-approved and are not interchangeable with brand-name products.

Investigational Drug Notice. Retatrutide is an investigational drug in active phase 3 trials (TRIUMPH program). It has not received FDA approval and is not legally available outside trial enrollment. FormBlends does not sell, supply, or facilitate access to retatrutide.

Results Disclaimer. Weight-loss percentages cited from clinical trials reflect mean outcomes in study populations. Individual results vary based on adherence, baseline weight, lifestyle, and biology. Trial data does not predict any specific patient's outcome.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly or Novo Nordisk.